About
Come to the one forum that will help you revise your strategies to adapt to new industry standards.
Emerging from a turbulent year of new case law, a resurgence of the proposed PTO rules, uncertainty associated with a new administration, and tough economic conditions, biotech patent practitioners must prepare for a new phase in this ever-evolving field. And with groundbreaking legislation regarding patent reform and follow-on biologics on the horizon, patent counsel must rise to the challenge to overcome increasing rejections, promote innovation and maximize profitability.
With this in mind, ACI’s 11th Advanced Forum on Biotech Patents once again brings together a high-caliber team of experienced biotech patent counsel who will share their collective knowledge and provide you with the most up to date strategies you can immediately incorporate into your practice.
Dedicated to the unique challenges faced by the biotech industry, your expert faculty will uncover critical insights involving:
- Developing a practical approach to follow-on biologics
- Preparing for the rule changes rising out of the Tafas decision
- Strategically avoiding rejection in diagnostic, method of treatment, and method of screening claims
- Delving into techniques to defeat charges of inequitable conduct
- Insights into key rule changes in foreign patent offices, including a special presentation on the EPO and EU patent litigation
- Overcoming challenges to antibody patent prosecution
Add value to your experience by attending our highly successful, interactive and in-depth Master Class on Drafting Successful Patent Applications for Biotechnology Inventions where you will learn how to master the art of drafting complex patent applications for your biotech inventions.
About
Come to the one forum that will help you revise your strategies to adapt to new industry standards.
Emerging from a turbulent year of new case law, a resurgence of the proposed PTO rules, uncertainty associated with a new administration, and tough economic conditions, biotech patent practitioners must prepare for a new phase in this ever-evolving field. And with groundbreaking legislation regarding patent reform and follow-on biologics on the horizon, patent counsel must rise to the challenge to overcome increasing rejections, promote innovation and maximize profitability.
With this in mind, ACI’s 11th Advanced Forum on Biotech Patents once again brings together a high-caliber team of experienced biotech patent counsel who will share their collective knowledge and provide you with the most up to date strategies you can immediately incorporate into your practice.
Dedicated to the unique challenges faced by the biotech industry, your expert faculty will uncover critical insights involving:
- Developing a practical approach to follow-on biologics
- Preparing for the rule changes rising out of the Tafas decision
- Strategically avoiding rejection in diagnostic, method of treatment, and method of screening claims
- Delving into techniques to defeat charges of inequitable conduct
- Insights into key rule changes in foreign patent offices, including a special presentation on the EPO and EU patent litigation
- Overcoming challenges to antibody patent prosecution
Add value to your experience by attending our highly successful, interactive and in-depth Master Class on Drafting Successful Patent Applications for Biotechnology Inventions where you will learn how to master the art of drafting complex patent applications for your biotech inventions.
Contents & Contributors
Prepairing for the Inevitable Enactment of Follow-on Biologics Legislation and Adopting a Practical Approach to Integrating FOB's into your Patent Strategies
Maggie Shafmaster, Ph.D., Sr. Vice President, Chief Patent Counsel, Genzyme Corp. (Cambridge, MA)
Barbara A. Fiacco, Partner, Foley Hoag LLP (Boston, MA)
Jeffrey P. Kushan, Partner, Sidley Austin LLP (Washington, D.C.)
Politics and Patents: Reassessing your Patent Strategy in Light of Current Changes
Michele Cimbala, Ph.D., Director, Sterne Kessler Goldstein & Fox PLLC (Washington, D.C.)
Harold C. Wegner, Partner, Foley & Lardner LLP (Washington, D.C.)
What's patentable? The Impact of Bilski and Related Precedents to Diagnostic Testing & Treatment Claims in the Biotech Patent Industry
Warren D. Woessner, J.D., Ph.D., Founding Shareholder, Schwegman Lundberg & Woessner (Minneapolis, MN)
Stephen Albainy-Jenei, Member, Frost Brown Todd LLC (Cincinnati, OH)
Kevin E. Noonan, Ph.D., Partner, McDonnell Boehnen Hulbert & Berghoff LLP, (Chicago, IL)
Deciphering the Impact of In re Kubin on Application of §103 Obviousness Requirements
K. Shannon Mrksich, Ph.D., Shareholder, Chair of Biotech Practice Group, Brinks Hofer Gilson & Lione (Chicago, IL)
Janis K. Fraser, Ph.D., Principal, Fish & Richardson P.C. (Boston, MA)
Strategies for Patenting Biotechnology Inventions with Evolving §112 Jurisprudence
Anne Brown, Ph.D., Partner, Thompson Hine LLP (Cleveland, OH)
Jennifer Gordon, Ph.D., Partner, Baker Botts LLP (New York, NY)
Cultivating Proactive Prosecution Strategies to Overcome Charges of Inequitable Conduct
Michael K. Levy, Partner, Kenyon & Kenyon LLP (New York, NY)
William C. Coppola, Head – Patent Prosecution, Bio-genomics, Sanofi-Aventis, (Union, NJ)
Developing Global Biotech Patent Strategies and Indentifying Key Rule Changes in Foreign Patent Offices
Lesley Rapaport MSc., LL.B., Associate Chair,Vancouver Biotechnology Practice Group, Borden Ladner Gervais LLP (Vancouver, Canada)
Elizabeth N. Spar, Associate, Edwards, Angell, Palmer & Dodge LLP, (Boston, MA)
Spotlight Presentation: European Biotech Patent Law
Adrian Tombling, European and UK Patent Attorney, Withers & Rogers LLP, (London, UK)
Marjan Noor, Partner, Howrey (London, UK)
Tactics for Breaking Through the Challenges Associated with Antibody Patent Prosecution
Len Smith, Senior Intellectual Property Counsel, Novo Nordisk (Princeton, NJ)
Dr. Hans-Rainer Jaenichen, European Patent Attorney, Vossius & Partner, (Munich, Germany)
Publication Details